Bard building surgical products line through $100 mil. merger with MedChem.
This article was originally published in The Gray Sheet
Executive Summary
BARD BUILDING SURGICAL PRODUCTS LINE WITH $100 MIL. MEDCHEM MERGER, the latest deal in Bard's ongoing acquisition progrm. Bard and MedChem jointly announced on May 24 that their boards had approved a definitive agreement for a stock-for-stock merger. With the deal, Bard would add Woburn, Massachusetts-based MedChem Products' lines of hemostasis, wound closure, and IV drug therapy catheter devices to its product portfolio.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.